Post-Marketing Surveillance (Use-results Surveillance) With Esperoct. A Multi-centre, Prospective, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Esperoct in Haemophilia A Patients Under Routine Clinical Practice Conditions in Japan
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 02 Jun 2025 Status changed from recruiting to completed.
- 13 Aug 2021 Planned End Date changed from 30 Apr 2025 to 28 Feb 2025.
- 13 Aug 2021 Planned primary completion date changed from 30 Apr 2025 to 28 Feb 2025.